Roche: The US and Asia outsprint Europe in life science sector

Slow regulatory processes and an unwillingness to pay the price for new medicines are contributing factors to Europe losing its significance as the home of drug development, criticizes Roche CEO.

Europe risks losing the race to win the favor of pharmaceutical companies, CEO at Roche Severin Schwan tells business daily Børsen.

He highlights easier access to health data and a willingness to reward innovation as deciding factors in explaining why the US and Asia are surpassing Europe in the pharmaceutical industry.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs